Last ¥2,956 JPY
Change Today -19.00 / -0.64%
Volume 76.9K
4585 On Other Exchanges
Symbol
Exchange
Tokyo
As of 2:00 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

umn pharma inc (4585) Snapshot

Open
¥2,949
Previous Close
¥2,975
Day High
¥2,993
Day Low
¥2,900
52 Week High
09/19/13 - ¥4,750
52 Week Low
03/27/14 - ¥2,020
Market Cap
25.0B
Average Volume 10 Days
72.6K
EPS TTM
¥-491.59
Shares Outstanding
8.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UMN PHARMA INC (4585)

Related News

No related news articles were found.

umn pharma inc (4585) Related Businessweek News

No Related Businessweek News Found

umn pharma inc (4585) Details

UMN Pharma Inc. engages in the development and manufacture of biopharmaceuticals in Japan and internationally. The company’s products include UMN-0502, a seasonal influenza vaccine; UMN-0501 and UMN-0901, which are pandemic influenza vaccines; and UMN-2003, a norovirus VLP + rotavirus VP6 non-live injectable trivalent vaccine for the prevention of causative agents of acute gastroenteritis. The company was incorporated in 2004 and is headquartered in Yokohama, Japan.

91 Employees
Last Reported Date: 03/31/14
Founded in 2004

umn pharma inc (4585) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

umn pharma inc (4585) Key Developments

UMN Pharma Inc. to Report Q1, 2014 Results on Apr 30, 2014

UMN Pharma Inc. announced that they will report Q1, 2014 results on Apr 30, 2014

UMN Pharma Inc., Annual General Meeting, Mar 28, 2014

UMN Pharma Inc., Annual General Meeting, Mar 28, 2014.

Daiichi Sankyo and UMN Pharma to Collaborate on Norovirus Vaccine

Daiichi Sankyo and UMN Pharma are set to collaborate on developing a vaccine for norovirus.Under the agreement, UMN will provide Daiichi Sankyo exclusive access to its recombinant norovirus Virus Like Particle antigen, which it produced using a cell-culture manufacturing method that utilizes the Baculovirus Expression Vector System. Daiichi Sankyo will then use a novel device to explore the possibility of creating a norovirus vaccine. Norovirus is one of the leading causes of infectious gastroenteritis. Though deaths from norovirus in the developed world are rare, they are still fairly common in developing countries and are caused primarily by dehydration from vomiting and other means of fluid loss than by the virus itself.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4585:JP ¥2,956.00 JPY -19.00

4585 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4585.
View Industry Companies
 

Industry Analysis

4585

Industry Average

Valuation 4585 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 182.8x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 116.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UMN PHARMA INC, please visit www.umnpharma.com/en. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.